Caught this filing from a couple months back - some fund dumped nearly 75 million in Xenon stock. Xenon was trading around 42 bucks at the time, so they moved like 1.8 million shares. Not huge, but enough to trim their position from meaningful to just 2.6% of the portfolio. Honestly the timing was interesting because the big catalyst was supposed to be March Phase 3 data for their seizure drug. They had 380 patients in the trial, so we're talking legit late-stage stuff. The fund basically said 'we like Xenon enough to keep some skin in the game, but not enough to go all-in before the data.' Smart hedging honestly. Xenon's been up like 6% over the past year which is pretty meh for biotech. The question now is whether those Phase 3 results actually moved the needle or if it's still waiting for that big catalyst moment. Diversification inside biotech really does matter when you're dealing with binary events like this.